v3.24.2.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 573,171 $ 574,962
Accounts receivable, net 38,651 54,605
Inventory 49,294 51,397
Prepaid expenses and other current assets 17,063 17,830
Interest rate cap 6,575 0
Government funding receivable 608 1,118
Total current assets 685,362 699,912
Property and equipment, net 165,503 162,900
Goodwill 326,029 326,029
Intangible assets, net 207,249 220,987
Other assets 63,465 77,622
Total assets 1,447,608 1,487,450
Current liabilities:    
Accrued expenses and other current liabilities 40,719 60,237
Deferred revenue 2,078 3,360
Current portion of long-term debt 5,440 5,440
Current portion of finance lease liabilities 710 633
Total current liabilities 68,552 87,468
Long-term debt, less current portion 517,083 518,707
Finance lease liabilities, less current portion 31,527 31,897
Other long-term liabilities 54,032 59,494
Total liabilities 671,194 697,566
Commitments and contingencies (Note 6)
Stockholders’ equity:    
Additional paid-in capital 168,337 128,503
Retained earnings 266,074 285,737
Total stockholders’ equity attributable to Maravai LifeSciences Holdings, Inc. 436,933 416,753
Non-controlling interest 339,481 373,131
Total stockholders’ equity 776,414 789,884
Total liabilities and stockholders’ equity 1,447,608 1,487,450
Class A Common Stock    
Stockholders’ equity:    
Common stock 1,415 1,322
Class B Common Stock    
Stockholders’ equity:    
Common stock 1,107 1,191
Nonrelated Party    
Current liabilities:    
Accounts payable 12,536 10,729
Related Party    
Current liabilities:    
Accounts payable $ 7,069 $ 7,069

Source